BIOCON Stock View

Biocon Ltd
stock-view-header

₹ 266.9

icon 1.90 | 0.72
Market Cap ₹( Cr.)
318,856.30
Proj. P/E (x)
34.24
Proj. P/BV (x)
1.60
Proj. ROE (%)
5.04
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)
154,230.41

Stock View

BUY

Last Updated On.
24-Sep-2023
 

The average score for Biocon Ltd stands at 4 against 5, three months back.

Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
262.05
100 DMA(₹)
254.67
200 DMA(₹)
245.87
52 Weeks Range
191.60     299.00

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required